Tetrahydrocarbazolones are disclosed of formula (I): <IMAGE> wherein R<1> is H or a group C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylC1-4alkyl, C3-6 alkenyl, C3-10 alkynyl, phenyl, phenylC1-3alkyl, -CO2R<6>, COR<6>, -CONR<6>R<7> or - SO2R<5> (wherein R<6> and R<7>, which may be the same or different, each represents a hydrogen atom, a C1-6 alkyl or C3-7 cycloalkyl group, or a phenyl or a phenylC1-4alkyl group in which the phenyl group is optionally substituted by one or more C1-4 alkyl, C1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R<6> does not represent a hydrogen atom when R<1> represents a group -CO2R<6> or -SO2R<6>); one of the groups represented by R<2>, R<3> and R<4> is H or C1-6 alkyl, C3-7 cycloalkyl, C2-6 alkenyl or phenylC1-3alkyl and each of the other two groups independently represents H or C1-6 alkyl; R<5> represents C1-6 alkyl; and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety and nausea and vomiting.
IMIDAZOLYLMETHYLCARBAZOLONDERIVATE UND VERFAHREN ZU IHRER HERSTELLUNG